The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Open accessAbstract
BACKGROUND Maintenance therapy following autologous stem cell transplantation (ASCT) can delay disease progression and prolong survival in patients with multiple myeloma. Ixazomib is ideally suited for maintenance therapy given its convenient once-weekly oral dosing and low toxicity profile. In this study, we aimed to determine the safety and efficacy of ixazomib as maintenance therapy following ASCT. METHODS The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study took place in 167 clinical or hospital sites in 30 countries in Europe, the Middle East, Africa, Asia, and North and South America. Eligible participants were adults with a confirmed diagnosis of symptomatic multiple myeloma according to International Myeloma Working Group criteria who had achieved at least a partial response after undergoing standard-of-care induction therapy followed by high-dose melphalan (200 mg/m2) conditioning and single ASCT within 12 months of diagnosis. Patients were randomly assigned in a 3:2 ratio to oral ixazomib or matching placebo on days 1, 8, and 15 in 28-day cycles for 2 years following induction, high-dose therapy, and transplantation. The initial 3 mg dose was increased to 4 mg from cycle 5 if tolerated during cycles 1-4. Randomisation was stratified by induction regimen, pre-induction disease stage, and response post-transplantation. The primary endpoint was progression-free survival (PFS) by intention-to-treat analysis. Safety was assessed in all patients who received at least one dose of ixazomib or placebo, according to treatment actually received. This trial is registered with ClinicalTrials.gov, number NCT02181413, and follow-up is ongoing. FINDINGS Between July 31, 2014, and March 14, 2016, 656 patients were enrolled and randomly assigned to receive ixazomib maintenance therapy (n=395) or placebo (n=261). With a median follow-up of 31 months (IQR 27·3-35·7), we observed a 28% reduction in the risk of progression or death with ixazomib versus placebo (median PFS 26·5 months [95% CI 23·7-33·8] vs 21·3 months [18·0-24·7]; hazard ratio 0·72, 95% CI 0·58-0·89; p=0·0023). No increase in second malignancies was noted with ixazomib therapy (12 [3%] patients) compared with placebo (eight [3%] patients) at the time of this analysis. 108 (27%) of 394 patients in the ixazomib group and 51 (20%) of 259 patients in the placebo group experienced serious adverse events. During the treatment period, one patient died in the ixazomib group and none died in the placebo group. INTERPRETATION Ixazomib maintenance prolongs PFS and represents an additional option for post-transplant maintenance therapy in patients with newly diagnosed multiple myeloma. FUNDING Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical Company.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Self-citationLenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060
Self-citationLenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793
Self-citationAutologous Transplantation and Maintenance Therapy in Multiple Myeloma
Palumbo, A., Cavallo, F., Gay, F., Di Raimondo, F., Ben Yehuda, D., Petrucci, M. T., Pezzatti, S., Caravita, T., Cerrato, C., Ribakovsky, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402888 · Cited by 778
Self-citationMcCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Bringhen, S., Musto, P., Anderson, K. C., Caillot, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6679 · Cited by 698
Self-citationBarlogie, B., Kyle, R. A., Anderson, K. C., Greipp, P. R., Lazarus, H. M., Hurd, D. D., McCoy, J., Moore, D. F., Dakhil, S. R., Lanier, K. S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5807 · Cited by 495
Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., et al. (2018) · Leukemia · doi:10.1038/leu.2017.211 · Cited by 200
Self-citationManagement of multiple myeloma: a systematic review and critical appraisal of published studies
Kumar, A., Loughran, T., Alsina, M., Durie, B. G., & Djulbegovic, B. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01077-5 · Cited by 113
Transplantation for multiple myeloma: who, when, how often?
(2003) · Blood · doi:10.1182/blood-2003-01-0073 · Cited by 88
Research works printed but not linked: 19
- Palumbo, 2012, Continuous lenalidomide treatment for newly diagnosed multiple myeloma, N Engl J Med, 366, 1759, 10.1056/NEJMoa1112704 · DOI · Paper page
- Sonneveld, 2012, Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial, J Clin Oncol, 30, 2946, 10.1200/JCO.2011.39.6820 · DOI · Paper page
- Isoda, 2018, Bortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: a multicenter phase II clinical trial, Int J Hematol, 108, 39, 10.1007/s12185-018-2448-9 · DOI
- Gupta, 2017, Dose and schedule selection of the oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma: clinical and model-based analyses, Target Oncol, 12, 643, 10.1007/s11523-017-0524-3 · DOI
- Rajkumar, 2017, Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1, Blood, 117, 4691, 10.1182/blood-2010-10-299487 · DOI · Paper page
- O'Brien, 1979, A multiple testing procedure for clinical trials, Biometrics, 35, 549, 10.2307/2530245 · DOI · Paper page
- Attal, 1996, A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome, N Engl J Med, 335, 91, 10.1056/NEJM199607113350204 · DOI · Paper page
- Blade, 2003, High-dose therapy in multiple myeloma, Blood, 102, 3469
- 2001, Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients, Br J Haematol, 113, 1020, 10.1046/j.1365-2141.2001.02857.x · DOI · Paper page
- Berenson, 2002, Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients, Blood, 99, 3163, 10.1182/blood.V99.9.3163 · DOI · Paper page
- Attal, 2006, Maintenance therapy with thalidomide improves survival in patients with multiple myeloma, Blood, 108, 3289, 10.1182/blood-2006-05-022962 · DOI · Paper page
- Spencer, 2009, Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure, J Clin Oncol, 27, 1788, 10.1200/JCO.2008.18.8573 · DOI · Paper page
- Sengsayadeth, 2017, Posttransplant maintenance therapy in multiple myeloma: the changing landscape, Blood Cancer J, 7, e545, 10.1038/bcj.2017.23 · DOI
- Moreau, 2017, Blood, 130, 2021
- Gay, 2018, Maintenance treatment and survival in patients with myeloma: a systematic review and network meta-analysis, JAMA Oncol, 4, 1389, 10.1001/jamaoncol.2018.2961 · DOI
- Gupta, 2018, Model-informed drug development for ixazomib, an oral proteasome inhibitor, Clin Pharmacol Ther
- Gupta, 2018, Clinical pharmacology of ixazomib: the first oral proteasome inhibitor, Clin Pharmacokinet
- Patel, 2017, Update on a phase II study of ixazomib with lenalidomide as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma, Blood, 130, 437
- Pulte, 2018, FDA approval summary: lenalidomide as maintenance therapy after autologous stem cell transplant in newly diagnosed multiple myeloma, Oncologist, 23, 734, 10.1634/theoncologist.2017-0440 · DOI
Cited by
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationMultiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Self-citationvan de Donk, N. W. C. J., Pawlyn, C., & Yong, K. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 869
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 789
Self-citationThe role of ubiquitination in tumorigenesis and targeted drug discovery
Deng, L., Meng, T., Chen, L., Wei, W., & Wang, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0107-0 · Cited by 744
Self-citation
Metadata
- Authors
- Dimopoulos, M. A., Gay, F., Schjesvold, F., Beksac, M., Hajek, R., Weisel, K. C., Goldschmidt, H., Maisnar, V., Moreau, P., Min, C. K., Pluta, A., Chng, W.-J., Kaiser, M., Zweegman, S., Mateos, M.-V., Spencer, A., Iida, S., Morgan, G., Suryanarayan, K., Teng, Z., Skacel, T., Palumbo, A., Dash, A. B., Gupta, N., Labotka, R., Rajkumar, S. V., Bar, D., Basso, A., Fantl, D., He, S., Horvath, N., Lee, C., Rowlings, P., Taylor, K., Spencer, A., Cochrane, T., Kwok, F., Ramanathan, S., Agis, H., Zojer, N., Kentos, A., Offner, F., Van Droogenbroeck, J., Wu, K. L., Maiolino, A., Martinez, G., Zanella, K., Capra, M., Araújo, S., Gregora, E., Hajek, R., Maisnar, V., Pour, L., Scudla, V., Spicka, I., Abildgaard, N., Andersen, N., Jensen, B. A., Helleberg, C., Plesner, T., Salomo, M., Svirskaite, A., Delarue, R., Moreau, P., Blau, I., Goldschmidt, H., Schieferdecker, A., Teleanu, V., Munder, M., Röllig, C., Salwender, H.-J., Fuhrmann, S., Weisel, K., Duerig, J., Zeis, M., Klein, S., Reimer, P., Schmidt, C., Scheid, C., Mayer, K., Hoffmann, M., Sosada, M., Dimopoulos, A., Delimpasi, S., Kyrtsonis, M.-C., Anagnostopoulos, A., Nagy, Z., Illés, Á., Egyed, M., Borbényi, Z., Mikala, G., Dally, N., Horowitz, N., Gutwein, O., Nemets, A., Vaxman, I., Shvetz, O., Trestman, S., Ruchlemer, R., Nagler, A., Tadmor, T., Rouvio, O., Preis, M., Gay, F., Cavo, M., De Rosa, L., Musto, P., Cafro, A., Tosi, P., Offidani, M., Corso, A., Rossi, G., Liberati, A. M., Bosi, A., Suzuki, K., Iida, S., Nakaseko, C., Ishikawa, T., Matsumoto, M., Nagai, H., Sunami, K., Chou, T., Akashi, K., Takezako, N., Hagiwara, S., Eom, H. S., Jo, D.-Y., Kim, J. S., Lee, J. H., Min, C. K., Yoon, S. S., Yoon, D. H., Kim, K., Zweegman, S., Levin, M.-D., Vellenga, E., Minnema, M., Schjesvold, F., Waage, A., Haukås, E., Grosicki, S., Pluta, A., Robak, T., Marques, H., Bergantim, R., Campilho, F., Chng, W. J., Goh, Y. T., McDonald, A., Rapoport, B., Álvarez Rivas, M. A., De Arriba de La Fuente, F., González Montes, Y., Martin Sanchez, J., Mateos, M. V., Oriol Rocafiguera, A., Rosinol, L., San Miguel, J., Pérez de Oteyza, J., Encinas, C., Alegre-Amor, A., López-Guía, A., Axelsson, P., Carlson, K., Stromberg, O., Hansson, M., Hveding Blimark, C., Mueller, R., Chen, C.-C., Liu, T.-C., Huang, S.-Y., Wang, P.-N., Na Nakorn, T., Prayongratana, K., Beksac, M., Unal, A., Goker, H., Sonmez, M., Korenkova, S., Chaidos, A., Oakervee, H., Sati, H., Benjamin, R., Wechalekar, A., Garg, M., Kaiser, M., Ramasamy, K., Cook, G., Chantry, A., Jenner, M., Buadi, F., Berryman, R., & Janakiram, M.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 393
- Issue
- 10168
- Pages
- 253-264
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2904778784
- Cited by
- 237
- References
- 10
- FWCI
- 19.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(18)33003-4
- The paper
- Dimopoulos, M. A., Gay, F., Schjesvold, F., Beksac, M., Hajek, R., Weisel, K. C., Goldschmidt, H., Maisnar, V., Moreau, P., Min, C. K., Pluta, A., Chng, W.-J., Kaiser, M., Zweegman, S., Mateos, M.-V., Spencer, A., Iida, S., Morgan, G., Suryanarayan, K., . . . Janakiram, M. (2019). Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(18)33003-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.